ArticleScientific reports2023
A novel modified-curcumin 2.24 resolves inflammation by promoting M2 macrophage polarization.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Chemically modified curcumin in periodontal therapy: a scoping review.Evidence-based dentistry · 2026Article
- Review
- Emerging Role of the NLRP3 Inflammasome in the Onset of Oral Diseases and Its Potential as a Therapeutic Target.International journal of molecular sciences · 2026Review
- A novel modified-curcumin 2.24 suppresses MMPs in a periodontal-relevant cell culture model: a pilot study.Frontiers in oral health · 2026Article
- Innate Immunity Gene Variants Affect Periodontitis Susceptibility.Advances in experimental medicine and biology · 2026Article
- Review
- New Insights in Natural Bioactive Compounds for Periodontal Disease: Advanced Molecular Mechanisms and Therapeutic Potential.Molecules (Basel, Switzerland) · 2025Review
- Diabetes, periodontal disease, and novel therapeutic approaches- host modulation therapy.Frontiers in clinical diabetes and healthcare · 2025Review
- Treatment of T2DM-related inflammation and vascular injury by regulating cellular crosstalk in the islet microenvironment.Frontiers in endocrinology · 2025Review
- Curcumin in oral health: mechanisms, clinical evidence, and delivery strategies.Frontiers in pharmacology · 2025Review
- Global trends in research on aging associated with periodontitis from 2002 to 2023: a bibliometric analysis.Frontiers in endocrinology · 2024Article
- Host modulation therapy in periodontitis, diagnosis and treatment-status update.Frontiers in dental medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess resolving-like activity by a novel chemically-modified curcumin (CMC2.24) in a "two-hit" model of diabetes-associated periodontitis. Macrophages from rats were cultured in the presence/absence of either Lipopolysaccharide (LPS, 1st hit); or advanced-glycation-end products (AGE, 2nd hit); or both combined. CMC2.24 was added as treatment. The conditioned media were analyzed for MMP-9, cytokines (IL-1β, IL-6, TNF-α), resolvins (RvD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.